Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer

References

• Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630–1635.
   PubMed Web of Science ®Google Scholar
• Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468–2473.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene. 2000;19:2474–2488.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ishihara K, Hibi N. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19:2548–2556.
   PubMed Web of Science ®Google Scholar
• Simon AR, Vikis HG, Stewart S, et al. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science. 2000;290:144–147.
   PubMed Web of Science ®Google Scholar
• Berishaj M, Gao SP, Ahmed S, et al. STAT3 is tyrosinephosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9:R32.
   PubMed Web of Science ®Google Scholar
• Anand P, Thomas SG, Kunnumakkara AB, et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol. 2008;76:1590–1611.
   PubMed Web of Science ®Google Scholar
• Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269:81–83.
   PubMed Web of Science ®Google Scholar
• Bill MA, Bakan C, Benson DM, Jr, et al. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol Cancer Ther. 2009;8:2726–2735.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Turkson J, Carter-Su C, et al. Activation of STAT3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem. 2000;275:24935–24944.
   PubMed Web of Science ®Google Scholar
• Lin L, Hutzen B, Zuo M, et al. Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res. 2010;70:2445–2454.
   PubMed Web of Science ®Google Scholar
• Garcia R, Bowman TL, Niu G, et al. Constitutive activation of STAT3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001;20:2499–2513.
   PubMed Web of Science ®Google Scholar
• Coleman DR, Ren Z, Mandal PK, et al. Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor. J Med Chem. 2005;48:6661–6670.
   PubMed Web of Science ®Google Scholar
• Schust J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 2006;13:1235–1242.
   PubMed Web of Science ®Google Scholar
• Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits STAT3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005;102:4700–4705.
   PubMed Web of Science ®Google Scholar
• Chen J, Bai L, Bernard D, et al. Structure-based design of conformationally constrained cell-permeable STAT3 inhibitors. ASC Med Chem Lett. 2010;1:85–89.
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Trefry J, Brasdovich M, et al. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells. Clin Cancer Res. 2007;13:5010–5019.
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Raig T, Guenterberg K, et al. IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apopotsis. Cancer Res. 2008; 68:8351–8360.
   PubMed Web of Science ®Google Scholar
• Grisouard J, Shimizu T, Duek A, et al. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015;125:2131–2140.
   PubMed Web of Science ®Google Scholar
• He Z, He X, Chen Z, et al. Activation of the mTORC1 and STAT3 pathways promotes the malignant transformation of colitis in mice. Oncol Rep. 2014;32:1873–1880.
   PubMed Web of Science ®Google Scholar
• Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) protein. J Med Chem. 2012;55:6645–6668.
   PubMed Web of Science ®Google Scholar
• Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem. 2008;15:834–843.
   PubMed Web of Science ®Google Scholar
• Guschin D, Rogers N, Briscoe J, et al. A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. Embo J. 1995;14:1421–1429.
   PubMed Web of Science ®Google Scholar
• Minami M, Inoue M, Wei S, et al. STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci USA. 1996;93:3963–3966.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 2009;87:825–833.
   PubMed Web of Science ®Google Scholar
• Fletcher S, Page BDG, Zhang X, et al. Antagonism of the STAT3-STAT3 protein dimer with salicylic acid-based small molecules. ChemMedChem. 2011;6:1459–1470.
   PubMed Web of Science ®Google Scholar
• Jain N, Zhang J, Fong SL, et al. Repression of Stat3 activity by activation of mitogen-activated protein kinase (MAPK). Oncogene. 1998;17:3157–3167.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
   PubMed Web of Science ®Google Scholar
• Simonian PL, Grillot DA, Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 1997;90:1208–1216.
   PubMed Web of Science ®Google Scholar
• Xie TX, Wei D, Liu M, et al. STAT3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene. 2004;23:3550–3560.
   PubMed Web of Science ®Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105–115.
   PubMed Web of Science ®Google Scholar
• Wei D, Le X, Zheng L, et al. STAT3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 2003;22:319–329.
   PubMed Web of Science ®Google Scholar
• Real PJ, Sierra A, De Juan A, et al. Resistance to chemotherapy via STAT3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002;21:7611–7618.
   PubMed Web of Science ®Google Scholar
• Gritsko T, Williams A, Turkson J, et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res. 2006;12:11–19.
   PubMed Web of Science ®Google Scholar
• Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA. 2005;102:4700–4705.
   PubMed Web of Science ®Google Scholar
• Nagel-Wolfrum K, Buerger C, Wittig I, et al. Functional specialization of calreticulin domains. J Cell Biol. 2001;154:961–972.
   PubMed Web of Science ®Google Scholar